Background and aims: Endogenous opioids function as negative factors affecting the growth has been established. The most influential factor in the growth and differentiation of the proliferating cells is the opioid growth factor (OGF). Recently, some studies have been completed about the effects of opioid growth factor in the pathogenesis of diabetes and the beneficial effects of inhibition of this growth pathway have been demonstrated. The aim of this study was to investigate the effect of inhibition of opioids growth pathway, in proliferation and growth of testicular germ cells and spermatogenesis following experimental diabetes in adult mice.
Material and methods: Diabetes was induced in adult mice by Streptozotocin. Diabetic animals were treated with Naltrexone 15, 30 and 60 mg/kg for 60 days. At the end of the study, testicular and body weight was recorded, tissue samples were collected and histomorphometrical studies were performed under light microscope.
Results: The results showed that the use of naltrexone has a little effect on preventing diabetic weight loss. Histomorphometric indices such as tubular diameter and germinal epithelium height were improved dose dependently in naltrexone treated diabetic mice. The number of tubular germ cells was increased non-significantly in diabetic animals following administration of naltrexone. Improvement of microscopic indices of spermatogenesis was observed in naltrexone treated diabetic mice.
Conclusions: According to the results of this study and the role of naltrexone as OGF-OGF receptor inhibitor and up-regulating activity of naltrexone which leads to increased DNA synthesis and cell division process, the administration of naltrexone could be effective in reduction of diabetic induced alterations of spermatogenesis.
1. Yanardag R, Ozsoy-Sacan O, Bolkent S, Orak H, Karabulut-Bulan O. Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. Hum Exp Toxicol 24: 129-135, 2005.
2. Cai L, Chen S, Evans T, Deng DX, Mukherjee K, Chakrabarti S. Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism. Urol Res 28: 342-347, 2000.
7. Akil H, Watson SJ, Young E, Lewis ME, Katchaturian H, Walter JM. Endogenous opioids: biology and function. Annu Rev Neurosci 7: 223–255, 1984.
8. Zagon IS, McLaughlin PJ. Endogenous opioids systems regulate growth of neural tumor cells in culture. Brain Res 490: 14–25, 1989.
9. Zagon IS, McLaughlin PJ. Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system. Brain Res 542: 318–323, 1991.
10. Zagon IS, McLaughlin PJ. The role of endogenous opioids and opioid receptors in human and animal cancers. In: Stress and Immunity. Plotnikoff NP, Murgo AJ, Faith RE, Wybran J (Eds). CRC Press, Caldwell, NJ, pp 343–356, 1991.
11. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 38: 351–376, 2002.
12. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) 236: 1036–1050, 2011.
13. Yin D, Tao J, Lee DD et al. Recovery of islet beta-cell function in streptozotocin-induced diabetic mice: an indirect role for spleen. Diabetes 55: 3256-3263, 2006.
14. Yoon SH, Han EJ, Sung JH, Chung SH. Anti-diabetic effects of compound K versus metformin versus compound K-metformin combination therapy in diabetic db/db mice. Biol Pharm Bull 30: 2196-2200, 2007.
15. Shetty G, Wilson G, Huhtaniemi I, Shuttlesworth GA, Reissmann T, Meistrich ML. Gonadotropin-releasing hormone analogs stimulate and testosterone inhibits the recovery of spermatogenesis in irradiated rats. Endocrinology 141: 1735-1745, 2000.
16. Kianifard D, Rezaee F. Beneficial effects of coenzyme q 10 in reduction of testicular tissue alteration following induction of diabetes in adult rats. Roman J Diab Nut Metabol Dis 22: 19-27, 2015.
17. Vermes I, Steinmetz E, Schoorl J, van der Veen EA, Tilders FJ. Increased plasma levels of immunoreactive beta-endorphin and corticotrophin in non-insulin-dependent diabetes. Lancet 2: 725–726, 1985.
18. Kolta MG, Pierzchala K, Houdi AA, Van Loon GR. Effect of diabetes on the levels of two forms of Met-enkephalin in plasma and peripheral tissues of the rat. Neuropeptides 21: 55–63, 1992.
19. Kolta MG, Ngong JM, Rutledge LP, Pierzchala K, Van Loon GR. Endogenous opioid peptide mediation of hypoalgesic response in long-term diabetic rats. Neuropeptides 30: 335–344, 1996.
20. Fallucca F, Tonnarini G, Di Biase N, D’Alessandro M, Negri M. Plasma met-enkephalin levels in diabetic patients: influence of autonomic neuropathy. Metabolism 45: 1065–1068, 1996.
21. Negri M, Tonnarini G, D’Alessandro M, Fallucca F. Plasma enkephalin in type I diabetes. Metabolism 41: 460–461, 1992.
22. Greenberg J, Ellyin F, Pullen G, Ehrenpreis S, Singh SP, Cheng J. Methionine-enkephalin and beta-endorphin levels in brain, pancreas, and adrenals of db/db mice. Endocrinology 116: 328–331, 1985.
23. Timmers K, Voyles NR, Zalenski C, Wilkins S, Recant L. Altered endorphin, met- and leu-enkephalins, and enkephalin-containing peptides in pancreas and pituitary of genetically obese diabetic (db/db) mice during development of diabetic syndrome. Diabetes 35: 1143–1151, 1986.
24. Pieper GM, Mizoguchi H, Ohsawa M, Kamei J, Nagase H, Tseng LF. Decreased opioid-induced antinociception but unaltered G-protein activation in the genetic-diabetic NOD mouse. Eur J Pharmacol 401: 375–379, 2000.
25. Grover VS, Sharma A, Singh M. Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice. Eur J Pharmacol 399: 161–164, 2000.
26. Berman Y, Devi L, Carr KD. Effects of streptozotocin-induced diabetes on prodynorphin-derived peptides in rat brain regions. Brain Res 685: 129–134, 1995.
27. Andulla B, Varadacharyulu NCh. Antioxidant role of mulberry (Morus indica L.cv. Anantha) leaves in streptozotocin-diabetic rats. Clin Chim Acta 338: 3-10, 2003.
28. Bailey CJ, Turner RC. Metformin. New Eng J Med 334: 574-579, 1996.
29. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Eng J Med 333: 550-554, 1995.
30. Sawynok J, Pinsky C, LaBella FS. On the specificity of naloxone as an opiate antagonist. Life Sci 25: 1621–1632, 1979.
31. Immonen JA, Zagon IS, McLaughlin PJ. Topical Naltrexone as Treatment for Type 2 Diabetic Cutaneous Wounds. Adv Wound Care (New Rochelle) 3: 419-427, 2014.
32. Tsong SD, Phillips D, Halmi N et al. ACTH ZVND β-endorphin-related peptides are present in multiple sites in the reproductive tract of the male rat. Endocrinology 110: 2204-2206, 1982.
33. Adams ML, Sewing B, Forman JB, Meyer ER, Cicero TJ. Opioid-induced suppression of rat testicular function. J Pharmacol Exp Ther 266: 323-328, 1993.